Physician profile
Jessica Weiser
NPI 1619172541
$83,736.43
in general payments reported to CMS, 2019-2025
32 companies · $9,625 in 2025
The $9,625 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $11K · 2021: $23K · 2022: $17K · 2023: $5,511 · 2024: $1,250 · 2025: $9,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,613 · Food and Beverage: $6,611 · Education: $99.99 · Travel and Lodging: $62.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,613.31 |
| Food and Beverage | $6,610.56 |
| Education | $99.99 |
| Travel and Lodging | $62.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $63,937.74 | 2019-2025 | |
| Allergan, INC. | $11,353.46 | 2019-2021 | |
| Revance Therapeutics, INC. | $2,255.36 | 2024-2025 | Daxxify |
| Janssen Biotech, INC. | $1,050.44 | 2020-2025 | Tremfya |
| Abbvie INC. | $656.08 | 2020-2025 | Skyrizi |
| Sun Pharmaceutical Industries INC. | $529.12 | 2020-2025 | Winlevi, Absorica Ld |
| Viiv Healthcare Company | $377.61 | 2024-2025 | Apretude |
| Regeneron Healthcare Solutions, INC. | $371.28 | 2023-2025 | Dupixent |
| Amgen INC. | $357.74 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $328.27 | 2019-2024 | |
| Leo Pharma INC. | $327.23 | 2020-2025 | Anzupgo, Adbry |
| Arcutis Biotherapeutics, INC. | $306.72 | 2024-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $284.11 | 2019-2025 | Siliq, Cabtreo, Jublia |
| Incyte Corporation | $261.14 | 2021-2025 | Opzelura |
| Merz North America, INC. | $193.57 | 2022-2023 | Xeomin |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $163.98 | 2019-2025 | |
| Lilly USA, LLC | $138.12 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Almirall LLC | $127.00 | 2019-2025 | Seysara |
| Epi Health, LLC | $123.59 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $112.96 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $105.64 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $68.17 | 2022-2025 | Sotyktu |
| Botanix Sb INC | $57.40 | 2025 | Sofdra |
| Journey Medical Corporation | $41.03 | 2022 | |
| Novo Nordisk INC | $35.76 | 2023-2024 | Wegovy |
| Dermavant Sciences, INC. | $31.73 | 2022 | |
| Mission Pharmacal Company | $28.75 | 2019-2020 | |
| Genzyme Corporation | $28.07 | 2024 | |
| Encore Dermatology INC. | $24.75 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.79 | 2024 | |
| Sebela Pharmaceuticals INC. | $18.57 | 2021 | |
| Dermira, INC. | $18.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Weiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.